Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MET642 · 1 trial · 1 indication
Incidences of treatment-emergent adverse events
Incidences of clinically significant changes in vital signs
Incidences of clinically significant changes in laboratory tests
Incidences of clinically significant changes in ECGs
| Arm | Type | Description |
|---|---|---|
| MET642 high dose | EXPERIMENTAL | - |
| MET642 low dose | EXPERIMENTAL | - |
| MET642 Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| MET642 | DRUG | MET642 active treatment |
| Placebo | DRUG | Placebo comparator |
Inclusion Criteria: * Diagnosis of NASH via biopsy, magnetic resonance elastography (MRE), or transient elastography (TE, FibroScan) * Liver fat content ≥ 10% as measured by magnetic resonance imaging-proton density fat fraction (MRI-PDFF). Exclusion Criteria: * History of significant liver disea...
MET642 is an investigational small molecule being developed for nonalcoholic steatohepatitis, or NASH, a metabolic liver disease. It has been studied in a Phase 2 clinical trial in patients with NASH. MET642 is not approved for any indication and remains in clinical development.
MET642 targets FXR, the farnesoid X receptor. FXR is a nuclear receptor that regulates bile acid, lipid, and glucose metabolism, which is why it is being explored as a therapeutic target in NASH. MET642 is a small molecule designed to act on this receptor.
MET642 is being developed by Equillium, Inc., which trades under the ticker EQ. Equillium is the sponsor of the clinical program evaluating MET642 in NASH.
MET642 is in Phase 2 development. A Phase 2 study in patients with NASH has been completed. MET642 is investigational and has not been approved by the FDA for any indication.
MET642 has been evaluated in one clinical trial, NCT04773964, titled Study to Evaluate MET642 in Patients With NASH. This completed Phase 2 trial enrolled 215 patients in the United States, was randomized, double-blind, and placebo-controlled, and included patients aged 18 years and older.